Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Completed 4Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Breast Neoplasms 2043Neoplasms 1458Carcinoma, Non-Small-Cell Lung 1360Prostatic Neoplasms 1104Multiple Myeloma 870Leukemia, Myeloid, Acute 767Colorectal Neoplasms 710Neoplasm Metastasis 702Lung Neoplasms 696Melanoma 683Lymphoma 665Leukemia 595Lymphoma, Non-Hodgkin 592Leukemia, Lymphocytic, Chronic, B-Cell 535Ovarian Neoplasms 530Pancreatic Neoplasms 500Precursor Cell Lymphoblastic Leukemia-Lymphoma 483Recurrence 474Myelodysplastic Syndromes 424Lymphoma, Follicular 418Carcinoma, Renal Cell 410Head and Neck Neoplasms 407Glioblastoma 380Lymphoma, Large B-Cell, Diffuse 379Brain Neoplasms 374Hodgkin Disease 354Carcinoma, Hepatocellular 332Squamous Cell Carcinoma of Head and Neck 326Lymphoma, Mantle-Cell 306Sarcoma 286

Interventions

Nivolumab 5Ipilimumab 3relatlimab 1daratumumab 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Various Advanced Cancer × Clear all
NCT03143153 2026-02-17

CheckMate 648

Bristol-Myers Squibb

Phase 3 Completed
970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT02632409 2025-10-16

CheckMate 274

Bristol-Myers Squibb

Phase 3 Active not recruiting
709 enrolled 13 charts 1 FDA

Various Advanced Cancer

NCT02488759 2023-11-13

CheckMate358

Bristol-Myers Squibb

Phase 1/2 Completed
578 enrolled 19 charts

Various Advanced Cancer

NCT02387996 2022-11-01

A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer

Bristol-Myers Squibb

Phase 2 Completed
270 enrolled 14 charts

Various Advanced Cancer

NCT03130959 2022-08-09

CheckMate 908

Bristol-Myers Squibb

Phase 2 Completed
166 enrolled 33 charts

Various Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡